title: Modulation of forebrain electroencephalographic activity in halothane-anesthetized rat via actions of noradrenergic beta-receptors within the medial septal region.
abstract: The locus coeruleus (LC)-noradrenergic system modulates forebrain electroencephalographic (EEG) activity in halothane-anesthetized rat. For example, unilateral enhancement of LC neuronal activity increases cortical EEG (ECoG) and hippocampal EEG (HEEG) indices of arousal bilaterally (Berridge and Foote, 1991). Conversely, bilateral suppression of LC discharge activity increases EEG measures of sedation (Berridge, et al., 1993b). The EEG-activating effects of LC stimulation appear to involve noradrenergic beta-receptors (Berridge and Foote, 1991). Two candidate sites at which LC efferents could influence ECoG and HEEG are the medial septum/vertical limb of the diagonal band of Broca (MS) and the substantia innominata/nucleus basalis of Meynert (SI). To determine whether norepinephrine mediates such actions within either of these regions, the EEG effects of small infusions of a beta-agonist or antagonist into MS or SI were examined in halothane-anesthetized rat. Unilateral infusions (150 nl) of the beta-agonist isoproterenol (ISO) (3.75 microg, 17 nmol) into MS, but not SI (150-450 nl), elicited robust bilateral activation of ECoG and HEEG. Infusions of glutamate (0.5 microg, 3.0 nmol) into either MS or SI elicited bilateral ECoG and HEEG activation. Neither vehicle infusions into MS nor infusions of ISO into regions adjacent to MS altered forebrain EEG activity. Bilateral, but not unilateral, MS infusions of the beta-antagonist timolol (3.75 microg, 8.7 nmol) decreased EEG indices of arousal in the lightly anesthetized preparation. Power spectral analyses provided quantitative confirmation of these qualitative observations. These results indicate that under these experimental conditions, noradrenergic efferents, presumably arising from LC, modulate forebrain EEG state via actions at beta-receptors located within MS. The results presented in the accompanying report extend these observations to the unanesthetized preparation and incorporate additional measures of behavioral state.
authors.affiliation: Psychology Department, University of Wisconsin, Madison, Wisconsin 53706-1611, USA.
authors.forename: C W
authors.initials: CW
authors.lastname: Berridge
authors.forename: S J
authors.initials: SJ
authors.lastname: Bolen
authors.forename: M S
authors.initials: MS
authors.lastname: Manley
authors.forename: S L
authors.initials: SL
authors.lastname: Foote
mesh_terms: D058665:Adrenergic beta-1 Receptor Agonists; D058671:Adrenergic beta-1 Receptor Antagonists; D058666:Adrenergic beta-2 Receptor Agonists; D058672:Adrenergic beta-2 Receptor Antagonists; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D018685:Anesthetics, Inhalation / Q000494:pharmacology*; D000818:Animals; D000918:Antibody Specificity; D001143:Arousal / Q000502:physiology; D001285:Atropine / Q000494:pharmacology; D002540:Cerebral Cortex / Q000502:physiology; D004299:Dopamine beta-Hydroxylase / Q000032:analysis / Q000276:immunology; D004569:Electroencephalography / Q000187:drug effects; D018698:Glutamic Acid / Q000494:pharmacology; D006221:Halothane / Q000494:pharmacology*; D006624:Hippocampus / Q000502:physiology; D007276:Injections, Intraventricular; D007545:Isoproterenol / Q000494:pharmacology; D008125:Locus Coeruleus / Q000502:physiology; D008297:Male; D008845:Microinjections; D018727:Muscarinic Antagonists / Q000494:pharmacology; D009474:Neurons / Q000737:chemistry / Q000201:enzymology; D009638:Norepinephrine / Q000819:agonists; D016548:Prosencephalon / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018342:Receptors, Adrenergic, beta-1 / Q000502:physiology*; D018343:Receptors, Adrenergic, beta-2 / Q000502:physiology*; D012686:Septal Nuclei / Q000737:chemistry / Q000502:physiology*; D013999:Timolol / Q000494:pharmacology
chemical_list: D058665:Adrenergic beta-1 Receptor Agonists; D058671:Adrenergic beta-1 Receptor Antagonists; D058666:Adrenergic beta-2 Receptor Agonists; D058672:Adrenergic beta-2 Receptor Antagonists; D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D018685:Anesthetics, Inhalation; D018727:Muscarinic Antagonists; D018342:Receptors, Adrenergic, beta-1; D018343:Receptors, Adrenergic, beta-2; D018698:Glutamic Acid; D001285:Atropine; D013999:Timolol; D004299:Dopamine beta-Hydroxylase; D007545:Isoproterenol; D006221:Halothane; D009638:Norepinephrine